Since the serum-cultured, triple-negative breast cancer cell line used in that study (MDA-MB 468) has been shown to have a mutation in p53 [38], the results imply that CEP-1347 could possibly exert its growth inhibitory effects on non-stem cancer cells in a p53-independent manner at least in some cancer types such as breast cancer. This evidence concerns the gene TP53 and breast cancer.